Revelation Biosciences Q2 net loss $8.4M; cash $12.1M, plans Phase 1b

REVELATION BIOSCIENCES, INC.

2024-Q2 EPS reported -$8.13

Net loss for Q2 2024 of $8.4M ($5.13 per share) vs $1.4M loss in Q2 2023.
Net loss for H1 2024 of $11.1M ($8.13 per share) vs net income of $4.7M in H1 2023.
Cash and equivalents $12.1M as of June 30, 2024, up from $12.0M at Dec 31, 2023.
Completed Phase 1 dosing of Gemini; safety endpoint met with biomarker activity.
Phase 1b study in CKD patients expected to start in H2 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.